文献速递心血管PETCTMRUS

改善系统性轻链淀粉样变性心脏淀粉样负荷的定量:重新定义早期疾病?

Improved Quantification of Cardiac Amyloid Burden in Systemic Light Chain Amyloidosis: Redefining Early Disease?
PubMed 文献 · JACC Cardiovasc Imaging · 2020-05-13

该研究前瞻性纳入45例受试者,分为活动性心脏受累组、活动性无心脏受累组和缓解期心脏受累组,采用[18F]florbetapir PET/CT、心脏磁共振和超声评估心脏淀粉样负荷。结果表明,传统标准判定无心脏受累的受试者中50%存在心脏淀粉样沉积的影像学证据,提示[18F]florbetapir PET和ECV扩展可识别临床前疾病。

要点

  • 传统标准无心脏受累的活动性AL淀粉样变性受试者中,50%经[18F]florbetapir PET显示心肌淀粉样沉积。
  • 缓解期心脏受累组尽管血液学缓解超过1年,仍存在ECV扩展、florbetapir RI升高和GLS异常。
  • 活动性心脏受累组florbetapir RI中位数0.110 min-1,GLS中位数-11%,为三组中负荷最大、功能最差。

关键影像表现/征象

  • 活动性心脏受累组心肌淀粉样负荷最大,[18F]florbetapir滞留指数中位数0.110 min-1(IQR 0.078–0.139 min-1)。
  • 活动性心脏受累组整体纵向应变中位数-11%(IQR -8%至-13%),为三组中最低。
  • 缓解期心脏受累组存在细胞外容积扩展、[18F]florbetapir滞留指数0.097 min-1(IQR 0.070–0.124 min-1)及GLS异常。

诊断标准与关键数值

  • 活动性无心脏受累组中,50%经先进影像指标发现心脏淀粉样沉积。
  • 活动性无心脏受累组中,20%经晚期钆增强识别心脏受累,20%存在细胞外容积升高,50%存在[18F]florbetapir滞留指数升高。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: The purpose of this study was to determine phenotypes characterizing cardiac involvement in AL amyloidosis by using direct (fluorine-18-labeled florbetapir {[18F]florbetapir} positron emission tomography [PET]/computed tomography) and indirect (echocardiography and cardiac magnetic resonance [CMR]) imaging biomarkers of AL amyloidosis.

BACKGROUND: Cardiac involvement in systemic light chain amyloidosis (AL) is the main determinant of prognosis and, therefore, guides management. The hypothesis of this study was that myocardial AL deposits and expansion of extracellular volume (ECV) could be identified before increases in N-terminal pro-B-type natriuretic peptide or wall thickness.

METHODS: A total of 45 subjects were prospectively enrolled in 3 groups: 25 with active AL amyloidosis with cardiac involvement (active-CA), 10 with active AL amyloidosis without cardiac involvement by conventional criteria (active-non-CA), and 10 with AL amyloidosis with cardiac involvement in remission for at least 1 year (remission-CA). All subjects underwent echocardiography, CMR, and [18F]florbetapir PET/CT to evaluate cardiac amyloid burden.

RESULTS: The active-CA group demonstrated the largest myocardial AL amyloid burden, quantified by [18F]florbetapir retention index (RI) 0.110 (interquartile range [IQR]: 0.078 to 0.139) min-1, and the lowest cardiac function by global longitudinal strain (GLS), median GLS -11% (IQR: -8% to -13%). The remission-CA group had expanded extracellular volume (ECV) and [18F]florbetapir RI of 0.097 (IQR: 0.070 to 0.124 min-1), and abnormal GLS despite hematologic remission for >1 year. The active-non-CA cohort had evidence of cardiac amyloid deposition by advanced imaging metrics in 50% of the subjects; cardiac involvement was identified by late gadolinium enhancement in 20%, elevated ECV in 20%, and elevated [18F]florbetapir RI in 50%.

CONCLUSIONS: Evidence of cardiac amyloid infiltration was found based on direct and indirect imaging biomarkers in subjects without CA by conventional criteria. The findings from [18F]florbetapir PET imaging provided insight into the preclinical disease process and on the basis of interpretation of expanded ECV on CMR and have important implications for future research and clinical management of AL amyloidosis. (Molecular Imaging of Primary Amyloid Cardiomyopathy [MICA]; NCT02641145).

来源:JACC Cardiovasc Imaging,查看原文。版权归原作者所有。

引用

  1. Cuddy SAM, Bravo PE, Falk RH, et al. Improved Quantification of Cardiac Amyloid Burden in Systemic Light Chain Amyloidosis: Redefining Early Disease? JACC Cardiovasc Imaging. 2020. PMID: 32417333. doi:10.1016/j.jcmg.2020.02.025

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。